BaroFold and Lonza sign evaluation agreement for protein refolding technology

Published: 16-Jan-2013

Lonza will focus on effectiveness of PreEMT for difficult to express microbial recombinant proteins


Lonza has signed a licensing agreement with BaroFold, a protein technology developer based in Aurora, CO, US, whereby Lonza will evaluate BaroFold’s PreEMT high pressure refolding technology for use in biological development refolding processes.

Lonza will focus on refolding difficult to express microbial products and the associated challenges of inclusion body processing. The PreEMT unit will be installed for evaluation at Lonza’s microbial development and manufacturing plant in Visp, Switzerland. The agreement includes an option for Lonza to extend the evaluation to cGMP production analysis.

‘This agreement allows us to evaluate BaroFold’s innovative high pressure refold technology as a complement to our existing XS Expression Technologies platform and offer customers a comprehensive toolbox for microbial recombinant protein production,’ said Janet White, Global Head of Lonza’s Custom Manufacturing Development Services business unit. ‘As a leader in the custom development and manufacturing industry, it is critical for Lonza to continue adopting novel manufacturing technologies that have the potential to streamline customer processes and ultimately reduce costs.’

Relevant companies

You may also like